impressive promotion , page-34

this company is not one app or trying to be an angry birds. They have multiple strings to their bow and a strong IP profile into COPD, sleep disorders, cough count and the like as well as asthma. Hard work has been done. Doom and gloom merchants seem happy to ignore the multiple avenues to market and opportunities for revenue and growth. The Gen2 app will be a revolution in asthma monitoring and be a subscription model. That means recurring revenue, not one of purchases. Dark days to be sure, but I don't buy for one minute the notion that they have nothing - especially from posters with no skin in the game.